Loading organizations...
§ Private Profile · London, United Kingdom
AI-based biotech company discovering and developing novel drugs using 3D deep-learning for oncology, focused on menin inhibitors.
Based in London, CHARM Therapeutics is an artificial intelligence-driven biotechnology company that utilizes proprietary 3D deep-learning technology to discover and develop novel oncology drugs. The firm leverages its DragonFold platform for rapid protein and ligand co-folding to design targeted therapies, with a primary clinical focus on next-generation menin inhibitors for acute myeloid leukemia. The enterprise, which grew to approximately 60 employees by late 2023, has raised a total of $130 million in equity financing, including a $50 million Series A round at a $100 million to $150 million post-money valuation and an $80 million Series B round in 2025. This capital was secured from a syndicate of prominent lead investors that includes Nvidia, OrbiMed, Khosla Ventures, and New Enterprise Associates. CHARM Therapeutics was founded in 2021 by Laksh Aithani and Nobel laureate David Baker.
CHARM Therapeutics has raised $130.0M across 2 funding rounds.
Key people at CHARM Therapeutics.
CHARM Therapeutics has raised $130.0M in total across 2 funding rounds.
CHARM Therapeutics has raised $130.0M in total across 2 funding rounds.
CHARM Therapeutics's investors include New Enterprise Associates, Mahesh Kudari, Andreessen Horowitz, Bowery Capital, Creandum, EQT Partners, Flex Capital, F-Prime Capital Partners, General Catalyst, Hyperplane Venture Capital, Khosla Ventures, Matthew McAviney.
Key people at CHARM Therapeutics.
CHARM Therapeutics has raised $130.0M across 2 funding rounds. Most recently, it raised $80.0M Series B in September 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2025 | $80M Series B | NEW Enterprise Associates, Mahesh Kudari | Andreessen Horowitz, Bowery Capital, Creandum, EQT Partners, Flex Capital, F Prime Capital, General Catalyst, Hyperplane Venture Capital, Khosla Ventures, Matthew Mcaviney, OrbiMed, Silence, Roger Ehrenberg, Shervin Pishevar, Susanna Campbell, F Prime Capital, NVIDIA | Announced |
| Jun 1, 2022 | $50M Series A | OrbiMed, Nihal Sinha | Andreessen Horowitz, Bowery Capital, Creandum, EQT Partners, Flex Capital, F Prime Capital, General Catalyst, Hyperplane Venture Capital, Khosla Ventures, Kinnevik, Matthew Mcaviney, Silence, Roger Ehrenberg, Shervin Pishevar, Susanna Campbell, Axial, Braavos Investment Advisers, Grep VC | Announced |
